Abstract
In a 42 year male, with hepatocellural carcinoma, confirmed by biopsy and a positive for somatostatin receptor liver scan, without any symptoms of neuroendocrine activity, it was decided to be treated with high therapeutic doses of [In-111-DTPA-D-Phe1] Octreotide [Mallinckrodt Br, Petten] and to abandon the conventional and, in the majority of the cases, hopeless cytostatic therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
E Krenning et al: Peptide receptor radionuclide therapy with [ Indium-111-DTPA-D-Phe] — Octreotide, J Nucl Med 38(5): 47P, 1997 [abstract]
Radiation Internal Dose Information Center, Oak Ridge Institute of Science and Education: MIRDOSE software version 3.0, J Nucl Med 37: 538–546,1996
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Basel AG
About this paper
Cite this paper
Limouris, G.S. et al. (1999). Auger and Conversion Electron Therapy with In-111 Pentetreotide in Hepatocellural Carcinoma. In: Bergmann, H., Köhn, H., Sinzinger, H. (eds) Radioactive Isotopes in Clinical Medicine and Research XXIII. Advances in Pharmacological Sciences. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8782-3_97
Download citation
DOI: https://doi.org/10.1007/978-3-0348-8782-3_97
Publisher Name: Birkhäuser, Basel
Print ISBN: 978-3-0348-9772-3
Online ISBN: 978-3-0348-8782-3
eBook Packages: Springer Book Archive